DAX21.254 +1,0%ESt505.206 +0,8%Top 10 Crypto16,50 -2,0%Dow44.157 +0,3%Nas20.009 +1,3%Bitcoin98.204 -1,4%Euro1,0402 -0,1%Öl78,61 -0,5%Gold2.754 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Siemens Energy ENER6Y Rheinmetall 703000 Tesla A1CX3T Oracle 871460 Apple 865985 Amazon 906866 Bayer BAY001 Deutsche Bank 514000 Microsoft 870747 Netflix 552484 SoftBank 891624 Deutsche Telekom 555750 SAP 716460 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Leitindex bleibt auf hohem Niveau: DAX kaum verändert erwartet -- Börsen in Asien uneinheitlich -- Samsung überrascht mit dünnerem Smartphone-Modell -- PUMA im Fokus
Top News
10 wichtige Fakten: Das sollten Sie am Donnerstag an der Börse wissen 10 wichtige Fakten: Das sollten Sie am Donnerstag an der Börse wissen
Ölpreise geben etwas nach - Das sind die Gründe Ölpreise geben etwas nach - Das sind die Gründe
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Amgen Aktie

NeuKaufenVerkaufen
Amgen Aktien-Sparplan
262,05 EUR -0,50 EUR -0,19 %
STU
274,33 USD +0,74 USD +0,27 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.141,89 Mrd. EUR

KGV23,07Div. Rendite2,96%

WKN867900

ISINUS0311621009

SymbolAMGN

Amgen Aktien News

DatumMeistgelesen
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
PR NewswireAMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
PR NewswireNEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
PR NewswireAMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
PR NewswireAMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS
PR NewswireAMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022
PR NewswireAMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS
PR NewswireAMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
PR NewswireAMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
PR NewswireAMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS
PR NewswireAMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND
PR NewswireAMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS
PR NewswireAMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM
PR NewswireAMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE
PR NewswireFDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
PR NewswireNEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTA...
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
PR NewswireNEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022
PR NewswireAMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
PR NewswireAMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT
PR NewswireAMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS
PR NewswireAMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
PR NewswireLUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
PR NewswireAMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022
PR NewswireAmgen To Present At The 32nd annual Oppenheimer Healthcare Conference
PR NewswireAMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022
PR NewswireGLOBAL BIOTECHNOLOGY LEADER AMGEN BREAKS GROUND ON NEW MANUFACTURING FACILITY IN NORTH CAROLINA
PR NewswireAMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND
PR NewswireNEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS
PR NewswireLUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
PR NewswireAMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW
Wer­bung

Amgen News

Amgen News: auf dieser Seite finden Sie alle Amgen News und Nachrichten zur Amgen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Amgen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Amgen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.